Pancreatic Cancer Clinical Trials

A listing of Pancreatic Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 883 clinical trials
  • None views
  • None views
  • None views
  • None views
Nivolumab Ipilimumab and Chemoradiation in Treating Patients With Locally Advanced Pancreatic Cancer.

Pancreatic ductal adenocarcinoma (PDAC) remains a dreadful disease due to its often advanced stage at diagnosis and poor sensitivity to chemotherapy. A locally unresectable tumor (locally advanced pancreatic cancer (LAPC)) is present in 30% of the cases and is defined as a surgically unresectable tumor encasing the adjacent arteries [celiac …

pancreatic ductal adenocarcinoma
ipilimumab
immunosuppressant
platelet count
treatment regimen
  • 0 views
  • 24 Nov, 2025
  • 1 location
Pulse-low-dose Rate (PLDR) Radiation in Pancreatic Cancer

Standard chemoradiation, followed by surgery are standard treatment plan for patients suffering from pancreatic adenocarcinoma. Due to damage to the surrounding healthy tissue caused by standard radiation, this study uses a new type of radiation plan- pulsed low-dose rate (PLDR) radiation , in combination with chemotherapeutic drug, gemcitabine, given weekly …

metastatic pancreatic cancer
celiac
kidney function tests
celiac disease
chemoradiotherapy
  • 0 views
  • 24 Nov, 2025
  • 1 location
NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer

Giving NBTXR3 followed by radiation therapy may work better to treat locally advanced or borderline-resectable pancreatic cancer compared to radiation therapy alone.

capecitabine
endoscopic ultrasound
resectable pancreatic cancer
platelet count
cancer
  • 0 views
  • 24 Nov, 2025
  • 1 location
Determination Safety and Tolerability of Epigenetic and Immunomodulating Drugs in Combination With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer.

A multi-center, open-label phase I/II study to to determine the safety and tolerability of Azacitidine and/or Romidepsin in combination with nab-Paclitaxel/Gemcitabine in patients with advanced pancreatic ductal adenocarcinoma (PDAC) (Part 1), followed by sequential immune targeting with programmed death-ligand (PD-L)1 blockade in combination with low-dose Lenalidomide (Part 2) in patients …

pancreatic ductal adenocarcinoma
drug test
breast ductal carcinoma
measurable disease
romidepsin
  • 0 views
  • 19 Feb, 2024
  • 8 locations
  • 0 views
  • 24 Nov, 2025
  • 2 locations
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

Eligibility Adults age 18 and older with pancreatic cancer, breast cancer, or a solid tumor that has not been cured by standard therapies. Also, children age 12-17 with a solid tumor (other than a muscle tumor) with no standard therapy options.

metarrestin
ct scan
solid tumor
inherited long qt syndrome
platelet count
  • 0 views
  • 24 Nov, 2025
  • 1 location